Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-small Cell Carcinoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Pancreatic Adenocarcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm
Conditions
Keywords
CD40 Antigen, Drug Therapy, Follicular Lymphoma, Hodgkin Disease, Immunotherapy, Indolent Lymphoma, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Monoclonal Antibody, Neoplasms, Neoplasm Metastasis, Solid tumor, Seattle Genetics
Brief summary
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.
Detailed description
The study will be conducted in the following parts: Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological dose (OBD) regimens in patients with solid tumors. The ability to increase the dose intensity (to give additional doses within a treatment cycle) may be evaluated. Part B: IV monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor expansion cohorts may be enrolled where patients will be treated with doses at or below the IV SEA-CD40 monotherapy MTD and/or OBD determined in Part A. Part C: IV monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40 monotherapy MTD and/or the OBD regimens in patients with lymphomas. The ability to increase the dose intensity (to give additional doses within a treatment cycle) may be evaluated. Part D: IV monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion cohorts may be enrolled where patients will be treated with doses at or below the IV SEA-CD40 monotherapy MTD and/or OBD determined in Part C. Part E: Combination therapy dose-regimen finding for solid tumors -- IV SEA-CD40 dose-escalation to define the MTD and/or the OBD regimen to be administered in combination with standard approved dose of pembrolizumab in patients with solid tumors. Part F: Combination therapy solid tumor expansion cohorts -- Disease-specific solid tumor expansion cohorts may be enrolled where patients will be treated with IV SEA-CD40 and pembrolizumab combination therapy; doses of SEA-CD40 will be at or below the MTD and/or OBD determined in Part E. Part G: Subcutaneous (SC) injection (injected under the skin) monotherapy dose-regimen finding for solid tumors -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the SC SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological dose (OBD) regimens in patients with solid tumors. Part H: SC monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor expansion cohorts may be enrolled where patients will be treated with doses at or below the SC SEA-CD40 monotherapy MTD and/or OBD determined in Part G. (Note: There is no Part I) Part J: SC monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to define the SC SEA-CD40 monotherapy MTD and/or the OBD regimens in patients with lymphomas. Part K: SC monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion cohorts may be enrolled where patients will be treated with doses at or below the SC SEA-CD40 monotherapy MTD and/or OBD determined in Part J. Part L: Combination therapy in pancreatic cancer -- Patients will be treated with SEA-CD40 doses at or below MTD and/or OBD. An established dose of pembrolizumab and a standard regimen of gemcitabine and nab-paclitaxel will be used. In Parts A, C, E, G, and J, a maximum feasible dose (MFD) will be defined if an MTD and/or OBD cannot be identified. Parts B, D, F, H, K. and L will explore the recommended dosing regimen once the MTD and/or OBD, or MFD (if the MTD and/or OBD cannot be identified) has been determined.
Interventions
DRUGIntravenous (IV) SEA-CD40
Given intravenously; schedule is cohort-specific.
DRUGPembrolizumab
Given intravenously; schedule is cohort-specific.
DRUGSubcutaneous (SC) SEA-CD40
Given subcutaneously on Day 1 every 3 weeks
DRUGGemcitabine
1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
DRUGNab-paclitaxel
125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
Sponsors
Merck Sharp & Dohme LLC
Seagen Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Histologically confirmed advanced malignancy, either: (a) Metastatic or unresectable solid malignancy; or (b) Classical Hodgkin lymphoma (HL), or diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma (including follicular lymphoma \[FL\]) * (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or progressive disease, specifically: (a) Solid tumors: Following at least 1 prior systemic therapy, and no further standard therapy is available for the patient's advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at least 2 prior systemic therapies in patients who are not candidates for autologous stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL: Following at least 1 prior systemic therapy; patients must have also received intensive salvage therapy unless they refused or were deemed ineligible; or (d) Indolent lymphoma: Following at least 1 prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists * (Combination Therapy - Part E and Part F) -- Histologically or cytologically confirmed advanced or metastatic solid malignancy for which pembrolizumab treatment is approved. In Part F, other advanced solid tumor indications may be eligible as identified by the Sponsor. * (Pancreatic Cancer Cohort - Part L) - Histologically or cytologically confirmed metastatic exocrine ductal adenocarcinoma of the pancreas not amenable to curative therapy. Patients must not have received any prior systemic therapy for metastatic disease; patients who have received prior therapy for non-metastatic pancreatic adenocarcinoma are eligible if therapy was fully completed more than 4 months before start of study treatment. * Representative baseline tumor tissue sample is available (Parts A-K) * Measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate baseline hematologic, renal, and hepatic function * Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy prior to initiation of study drug administration
Exclusion criteria
* Parts A-K 1. Prior chemotherapy, small molecule inhibitors, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies) within 4 weeks 2. Prior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative radiotherapy (to non-CNS disease) within 1 week 3. Prior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology doublet used as the prior line of therapy) 4. Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates within 4 weeks (or 2 weeks if patient experienced disease progression on the prior treatment) 5. Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient experienced disease progression on the prior treatment) * Part L 1. History of radiation pneumonitis 2. Neuropathy Grade 2 or higher 3. Has received prior therapy with an anti-PD-1, anti-PDL1, or anti-PD-L2 agent, with an agent directed to another stimulatory or co-inhibitory T-cell receptor 4. Has had allogenic tissue/solid organ transplant * All Parts 1. Recent or ongoing serious infections within 2 weeks 2. Known positivity for hepatitis B infection 3. Known active hepatitis C infection 4. Active autoimmune or auto-inflammatory ocular disease within 6 months 5. Known or suspected active organ-threatening autoimmune disease 6. Active central nervous system tumor or metastases * Patients with lymphomas: prior allogeneic SCT * Patients in Part E, F, or L: history of severe immune-mediated adverse reactions or severe hypersensitivity to pembrolizumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (Parts A-K) | Through 6 weeks following last dose, up to an average of 6 months |
| Incidence of laboratory abnormalities (Parts A-K) | Through 6 weeks following last dose, up to an average of 6 months |
| Objective response rate (ORR) per RECIST according to investigator assessment in the efficacy-evaluable population (Part L) | Through 6 weeks following last dose, up to an average of 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (Part L) | Through 6 weeks following last dose, up to an average of 6 months |
| ORR per iRECIST (Part L) | Through 6 weeks following last dose, up to an average of 6 months |
| ORR (Parts A-K) | Through 6 weeks following last dose, up to an average of 6 months |
| Disease control rate (All Parts) | Through 6 weeks following last dose, up to an average of 6 months |
| Duration of response (All Parts) | Up to approximately 6 years |
| Tmax (time of maximum observed concentration) | Through 6 weeks following last dose, up to an average of 6 months |
| Progression-free survival (All Parts) | Up to approximately 6 years |
| AUCinf (AUC from time 0 to infinity) | Through 6 weeks following last dose, up to an average of 6 months |
| Apparent total clearance | Through 6 weeks following last dose, up to an average of 6 months |
| T1/2 (apparent terminal elimination half-life) | Through 6 weeks following last dose, up to an average of 6 months |
| Incidence of antitherapeutic antibodies against SEA-CD40 | Through 6 weeks following last dose, up to an average of 6 months |
| Blood concentrations of SEA-CD40 | Through 6 weeks following last dose, up to an average of 6 months |
| AUClast (AUC from time 0 to last quantifiable timepoint) | Through 6 weeks following last dose, up to an average of 6 months |
| Overall survival (All Parts) | Up to approximately 6 years |
| Cmax (maximum observed concentration) | Through 6 weeks following last dose, up to an average of 6 months |
Countries
United States
Outcome results
None listed